Sarcoma Maintenance Therapy Shows Long-Term Survival With MASCT-I
Phase I data show MASCT-I maintenance was well tolerated in advanced sarcoma, with sustained antigen-specific immunity and encouraging long-term survival.
This section contains the website’s posts.